Junshi Biosciences and Impact Therapeutics Establish Joint Venture to Develop PARP Inhibitor Senaparib (IMP4297) in China
SHANGHAI and NANJING, China, Aug. 20 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, and Impact Therapeutics, a privately held clinical-stage biopharmaceutical company devoted to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, annouced today [...]